Logo image of ALPN

ALPINE IMMUNE SCIENCES INC (ALPN) Stock Fundamental Analysis

NASDAQ:ALPN - Nasdaq - US02083G1004 - Common Stock - Currency: USD

64.97  +0.01 (+0.02%)

After market: 64.99 +0.02 (+0.03%)

Fundamental Rating

4

Overall ALPN gets a fundamental rating of 4 out of 10. We evaluated ALPN against 558 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ALPN as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, ALPN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

ALPN had negative earnings in the past year.
ALPN had a negative operating cash flow in the past year.
ALPN had negative earnings in each of the past 5 years.
ALPN had negative operating cash flow in 4 of the past 5 years.
ALPN Yearly Net Income VS EBIT VS OCF VS FCFALPN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M -40M -60M

1.2 Ratios

ALPN has a Return On Assets of -9.86%. This is amongst the best in the industry. ALPN outperforms 87.99% of its industry peers.
ALPN has a Return On Equity of -11.07%. This is amongst the best in the industry. ALPN outperforms 90.05% of its industry peers.
Industry RankSector Rank
ROA -9.86%
ROE -11.07%
ROIC N/A
ROA(3y)-16.1%
ROA(5y)-29.01%
ROE(3y)-27.88%
ROE(5y)-54.08%
ROIC(3y)N/A
ROIC(5y)N/A
ALPN Yearly ROA, ROE, ROICALPN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALPN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALPN Yearly Profit, Operating, Gross MarginsALPN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -1K -2K -3K -4K -5K

8

2. Health

2.1 Basic Checks

ALPN does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALPN has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ALPN has been increased compared to 5 years ago.
ALPN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ALPN Yearly Shares OutstandingALPN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
ALPN Yearly Total Debt VS Total AssetsALPN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

An Altman-Z score of 64.87 indicates that ALPN is not in any danger for bankruptcy at the moment.
ALPN's Altman-Z score of 64.87 is amongst the best of the industry. ALPN outperforms 98.46% of its industry peers.
ALPN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 64.87
ROIC/WACCN/A
WACC9.11%
ALPN Yearly LT Debt VS Equity VS FCFALPN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 9.56 indicates that ALPN has no problem at all paying its short term obligations.
With a decent Current ratio value of 9.56, ALPN is doing good in the industry, outperforming 74.96% of the companies in the same industry.
A Quick Ratio of 9.56 indicates that ALPN has no problem at all paying its short term obligations.
With a decent Quick ratio value of 9.56, ALPN is doing good in the industry, outperforming 75.13% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.56
Quick Ratio 9.56
ALPN Yearly Current Assets VS Current LiabilitesALPN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

6

3. Growth

3.1 Past

ALPN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 60.82%, which is quite impressive.
Looking at the last year, ALPN shows a very strong growth in Revenue. The Revenue has grown by 118.80%.
Measured over the past years, ALPN shows a very strong growth in Revenue. The Revenue has been growing by 141.96% on average per year.
EPS 1Y (TTM)60.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)118.8%
Revenue growth 3Y84.73%
Revenue growth 5Y141.96%
Sales Q2Q%-25.09%

3.2 Future

The Earnings Per Share is expected to decrease by -13.31% on average over the next years. This is quite bad
Based on estimates for the next years, ALPN will show a very strong growth in Revenue. The Revenue will grow by 33.81% on average per year.
EPS Next Y-157.63%
EPS Next 2Y-70.39%
EPS Next 3Y-54.78%
EPS Next 5Y-13.31%
Revenue Next Year-56.25%
Revenue Next 2Y-32.39%
Revenue Next 3Y-34.72%
Revenue Next 5Y33.81%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ALPN Yearly Revenue VS EstimatesALPN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 500M 1B 1.5B
ALPN Yearly EPS VS EstimatesALPN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 5 -5 10 15

0

4. Valuation

4.1 Price/Earnings Ratio

ALPN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ALPN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALPN Price Earnings VS Forward Price EarningsALPN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALPN Per share dataALPN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

A cheap valuation may be justified as ALPN's earnings are expected to decrease with -54.78% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-70.39%
EPS Next 3Y-54.78%

0

5. Dividend

5.1 Amount

ALPN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

ALPINE IMMUNE SCIENCES INC

NASDAQ:ALPN (5/17/2024, 8:00:01 PM)

After market: 64.99 +0.02 (+0.03%)

64.97

+0.01 (+0.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-09 2024-05-09/amc
Earnings (Next)08-12 2024-08-12/amc
Inst Owners5.3%
Inst Owner Change0%
Ins Owners18.43%
Ins Owner Change0%
Market Cap4.46B
Analysts76
Price Target62.73 (-3.45%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)84.33%
Min EPS beat(2)33.62%
Max EPS beat(2)135.04%
EPS beat(4)4
Avg EPS beat(4)56.9%
Min EPS beat(4)29.29%
Max EPS beat(4)135.04%
EPS beat(8)5
Avg EPS beat(8)-18.51%
EPS beat(12)5
Avg EPS beat(12)-928.68%
EPS beat(16)6
Avg EPS beat(16)-710.5%
Revenue beat(2)2
Avg Revenue beat(2)164.17%
Min Revenue beat(2)96.1%
Max Revenue beat(2)232.25%
Revenue beat(4)3
Avg Revenue beat(4)89.84%
Min Revenue beat(4)-4.81%
Max Revenue beat(4)232.25%
Revenue beat(8)4
Avg Revenue beat(8)23.35%
Revenue beat(12)5
Avg Revenue beat(12)4.08%
Revenue beat(16)6
Avg Revenue beat(16)-4.07%
PT rev (1m)-0.81%
PT rev (3m)83.19%
EPS NQ rev (1m)3.87%
EPS NQ rev (3m)-9.12%
EPS NY rev (1m)0%
EPS NY rev (3m)-26.02%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-35.09%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-48.45%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 78.86
P/FCF N/A
P/OCF N/A
P/B 13.4
P/tB 13.4
EV/EBITDA N/A
EPS(TTM)-0.67
EYN/A
EPS(NY)-1.95
Fwd EYN/A
FCF(TTM)-1.18
FCFYN/A
OCF(TTM)-1.17
OCFYN/A
SpS0.82
BVpS4.85
TBVpS4.85
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -9.86%
ROE -11.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-16.1%
ROA(5y)-29.01%
ROE(3y)-27.88%
ROE(5y)-54.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 71.36%
Cap/Sales 0.74%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.56
Quick Ratio 9.56
Altman-Z 64.87
F-Score5
WACC9.11%
ROIC/WACCN/A
Cap/Depr(3y)57.41%
Cap/Depr(5y)96.93%
Cap/Sales(3y)0.9%
Cap/Sales(5y)11.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-157.63%
EPS Next 2Y-70.39%
EPS Next 3Y-54.78%
EPS Next 5Y-13.31%
Revenue 1Y (TTM)118.8%
Revenue growth 3Y84.73%
Revenue growth 5Y141.96%
Sales Q2Q%-25.09%
Revenue Next Year-56.25%
Revenue Next 2Y-32.39%
Revenue Next 3Y-34.72%
Revenue Next 5Y33.81%
EBIT growth 1Y22.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-66.67%
EBIT Next 3Y-35.27%
EBIT Next 5Y-25.05%
FCF growth 1Y-1436.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1405.54%
OCF growth 3YN/A
OCF growth 5YN/A